With the shares up about 30% from the time of my last article, I can't complain about how Nektar Therapeutics (NASDAQ:NKTR)
has been performing. While an improvement in sentiment on biotech
stocks in general certainly hasn't hurt, I also think Nektar is
benefiting from signs of life in the Movantik business, a clever deal
that may revive a cancer drug's commercial potential, and growing
optimism about an early-stage pipeline asset in cancer.
Between the passage of time, the deal with Daiichi Sankyo,
and a little more optimism about NKTR-214, I've added about $3 to my
fair value (with the simple passage of time accounting for about half of
that). With that, I'd say these shares still hold some appeal.
Read the full article here:
Incremental Progress At Nektar Therapeutics
No comments:
Post a Comment